Life Sciences Meets Lab Automation
SLAS is pleased to bring together the laboratory automation and life sciences research communities at the SLAS Europe 2025 Conference & Exhibition at the Congress Center Hamburg, 20-22 May.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 232 entries already.
SLAS is pleased to bring together the laboratory automation and life sciences research communities at the SLAS Europe 2025 Conference & Exhibition at the Congress Center Hamburg, 20-22 May.
The Technologiepark Heidelberg has been shaping Heidelberg‘s startup ecosystem with 100,000 sqm of lab and office spaces, individual startup support, and top events for over 40 years – offering ideal conditions for established companys and startups in the fields of life sciences, biotech, industry tech, and AI.
The landscape of macromolecule drug discovery is evolving rapidly, with oligonucleotides and peptides leading the way in innovative therapeutic applications. CDD Vault, a leading scientific data management system, significantly improves the way researchers manage macromolecule data by introducing a dedicated Macromolecule mode that seamlessly integrates with modern workflows.
After the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging long-term financing trends as well as the recent events in the US, which may also impact the biotech industry.
Cambridge-based 4basebio PLC announced the appointment of Gabe Longoria as Chief Commercial Officer.
During the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?
Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.
Dr Sonya Montgomery joined OSE Immunotherapeutics SA, based in Nantes, France, as Chief Development Officer.
Cambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
Kufstein-based Single Use Support appointed Darren Verlenden as CEO and strengthens leadership team.